Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2025 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

goodrx holdings inc. - GDRX

GDRX

Close Chg Chg %
3.77 0.09 2.39%

Closed Market

3.86

+0.09 (2.39%)

Volume: 2.20M

Last Updated:

Oct 23, 2025, 4:00 PM EDT

Trade Now

Company Overview: goodrx holdings inc. - GDRX

GDRX Key Data

Open

$3.77

 Day Range

3.74 - 3.90

52 Week Range

3.31 - 6.67

 Market Cap

$1.31B

Shares Outstanding

347.45M

 Public Float

81.47M

Beta

1.23

 Rev. Per Employee

N/A

P/E Ratio

40.63

 EPS

$0.09

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

5.83M

  

GDRX Performance

1 Week
 
 -1.57%
 
1 Month
 
 -6.68%
 
3 Months
 
 -24.60%
 
1 Year
 
 -39.29%
 
5 Years
 
 -92.82%
 

GDRX Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 15
Full Ratings ➔

About goodrx holdings inc. - GDRX

GoodRx Holdings, Inc. engages in the business of a consumer-focused digital healthcare platform. The firm offers consumers free access to transparent and lower prices for brand and generic medications, affordable and convenient medical provider consultations via telehealth, and comprehensive healthcare research and information. The company was founded by Trevor Bezdek and Douglas Joseph Hirsch in September 2011 and is headquartered in Santa Monica, CA.

GDRX At a Glance

GoodRx Holdings, Inc.
2701 Olympic Boulevard
Santa Monica, California 90404
Phone 1-855-268-2822 Revenue 792.32M
Industry Internet Software/Services Net Income 16.39M
Sector Technology Services 2024 Sales Growth 5.606%
Fiscal Year-end 12 / 2025 Employees 738
View SEC Filings

GDRX Valuation

P/E Current 41.918
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) 111.244
Price to Sales Ratio 2.302
Price to Book Ratio 2.456
Price to Cash Flow Ratio 9.92
Enterprise Value to EBITDA 12.08
Enterprise Value to Sales 2.422
Total Debt to Enterprise Value 0.283

GDRX Efficiency

Revenue/Employee 1,073,609.756
Income Per Employee 22,208.672
Receivables Turnover 4.926
Total Asset Turnover 0.532

GDRX Liquidity

Current Ratio 5.321
Quick Ratio 5.321
Cash Ratio 3.619

GDRX Profitability

Gross Margin 85.138
Operating Margin 11.27
Pretax Margin 3.971
Net Margin 2.069
Return on Assets 1.101
Return on Equity 2.205
Return on Total Capital 1.293
Return on Invested Capital 1.207

GDRX Capital Structure

Total Debt to Total Equity 74.985
Total Debt to Total Capital 42.852
Total Debt to Total Assets 39.147
Long-Term Debt to Equity 73.518
Long-Term Debt to Total Capital 42.014
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Goodrx Holdings Inc. - GDRX

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
745.42M 766.55M 750.26M 792.32M
Sales Growth
+35.36% +2.83% -2.12% +5.61%
Cost of Goods Sold (COGS) incl D&A
81.25M 118.81M 170.09M 117.75M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
37.64M 57.53M 111.77M 69.54M
Depreciation
7.10M 7.95M 8.90M 4.50M
Amortization of Intangibles
30.54M 49.58M 102.87M 65.04M
COGS Growth
+69.22% +46.22% +43.16% -30.77%
Gross Income
664.17M 647.74M 580.17M 674.57M
Gross Income Growth
+32.12% -2.47% -10.43% +16.27%
Gross Profit Margin
+89.10% +84.50% +77.33% +85.14%
2021 2022 2023 2024 5-year trend
SG&A Expense
636.47M 610.58M 528.80M 585.28M
Research & Development
125.86M 138.88M 133.44M 123.75M
Other SG&A
510.61M 471.70M 395.36M 461.53M
SGA Growth
-17.35% -4.07% -13.39% +10.68%
Other Operating Expense
- - - -
-
Unusual Expense
14.30M 46.83M 77.03M 25.52M
EBIT after Unusual Expense
13.41M (9.67M) (25.65M) 63.77M
Non Operating Income/Expense
59.00K 20.68M 26.81M 20.61M
Non-Operating Interest Income
59.00K 9.27M 32.17M 23.27M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
23.64M 34.24M 56.73M 52.92M
Interest Expense Growth
-15.30% +44.84% +65.66% -6.71%
Gross Interest Expense
23.64M 34.24M 56.73M 52.92M
Interest Capitalized
- - - -
-
Pretax Income
(10.18M) (23.23M) (55.57M) 31.46M
Pretax Income Growth
+96.65% -128.27% -139.21% +156.61%
Pretax Margin
-1.37% -3.03% -7.41% +3.97%
Income Tax
15.08M 9.60M (46.70M) 15.07M
Income Tax - Current - Domestic
2.17M 10.09M 18.86M 26.98M
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
12.91M (497.00K) (65.56M) (11.91M)
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(25.25M) (32.83M) (8.87M) 16.39M
Minority Interest Expense
- - - -
-
Net Income
(25.25M) (32.83M) (8.87M) 16.39M
Net Income Growth
+91.40% -29.99% +72.99% +284.82%
Net Margin Growth
-3.39% -4.28% -1.18% +2.07%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(25.25M) (32.83M) (8.87M) 16.39M
Preferred Dividends
- - - -
-
Net Income Available to Common
(25.25M) (32.83M) (8.87M) 16.39M
EPS (Basic)
-0.063 -0.0795 -0.0216 0.0425
EPS (Basic) Growth
+91.60% -26.19% +72.83% +296.76%
Basic Shares Outstanding
400.56M 412.86M 410.31M 385.74M
EPS (Diluted)
-0.063 -0.0795 -0.0216 0.0418
EPS (Diluted) Growth
+91.60% -26.19% +72.83% +293.52%
Diluted Shares Outstanding
400.56M 412.86M 410.31M 392.17M
EBITDA
65.34M 94.69M 163.15M 158.83M
EBITDA Growth
+126.73% +44.90% +72.30% -2.65%
EBITDA Margin
+8.77% +12.35% +21.75% +20.05%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 5.386
Number of Ratings 15 Current Quarters Estimate 0.095
FY Report Date 12 / 2025 Current Year's Estimate 0.373
Last Quarter’s Earnings 0.09 Median PE on CY Estimate N/A
Year Ago Earnings 0.34 Next Fiscal Year Estimate 0.456
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 11 5 11 11
Mean Estimate 0.10 0.10 0.37 0.46
High Estimates 0.11 0.13 0.40 0.51
Low Estimate 0.08 0.08 0.34 0.39
Coefficient of Variance 8.31 17.37 5.10 9.31

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 7 7 8
OVERWEIGHT 1 2 1
HOLD 6 6 8
UNDERWEIGHT 1 1 1
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Goodrx Holdings Inc. - GDRX

Date Name Shares Transaction Value
Jul 10, 2025 Ian T. Clark Director 34,497 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Jul 10, 2025 Ian T. Clark Director 100,150 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 Non-derivative transaction at $4.74 per share 474,711.00
Mar 24, 2025 Idea Men LLC Director N/A Disposition to the issuer of issuer equity secs pursant to Rule 16b-3 Non-derivative transaction at $4.2 per share 0.00
Mar 24, 2025 Idea Men LLC Director 7,000,000 Conversion of derivative security 0.00
Mar 17, 2025 Scott W. Wagner Director 253,618 Bona fide gift 0.00
Mar 17, 2025 Scott W. Wagner Director 189,386 Bona fide gift 0.00
Mar 17, 2025 Scott W. Wagner Director 125,154 Bona fide gift 0.00
Mar 11, 2025 Romin Nabiey Chief Accounting Officer 26,787 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 Romin Nabiey Chief Accounting Officer 61,205 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 Romin Nabiey Chief Accounting Officer 106,874 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.61 per share 492,689.14
Mar 11, 2025 Romin Nabiey Chief Accounting Officer 107,682 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 11, 2025 Romin Nabiey Chief Accounting Officer 105,449 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $4.61 per share 486,119.89
Mar 11, 2025 Romin Nabiey Chief Accounting Officer 109,640 Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 0.00
Mar 6, 2025 Christopher A. McGinnis See Remarks 1,096,937 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Christopher A. McGinnis See Remarks 716,479 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Wendy Barnes See Remarks; Director 2,828,232 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Wendy Barnes See Remarks; Director 409,416 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Mar 6, 2025 Wendy Barnes See Remarks; Director 1,842,374 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 24, 2025 Scott W. Wagner Director 94,182 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
Jan 6, 2025 Ronald Earl Bruehlman Director 32,284 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00

Goodrx Holdings Inc. in the News